Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1005-1011, November 2006

The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro

  • Erik Samén

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • ,
  • Jan-Olov Thorell

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • ,
  • Anna Fredriksson

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • ,
  • Sharon Stone-Elander

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • Department Clinical Neurosciences, Karolinska Institutet, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden. Tel.: +46 8 51775331; fax: +46 8 307346.

Received 7 September 2006; accepted 28 September 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0969-8051(06)00195-8

doi:10.1016/j.nucmedbio.2006.09.008

Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1005-1011, November 2006

Article Tools

* Image Usage & Resolution